VacZine Analytics  
MarketVIEW: Epstein-barr virus (EBV) vaccines

Published: July 2015

Epstein-barr virus (EBV) is a herpesvirus family that exclusively infects humans, over 95% of adults worldwide are infected. Primary EBV infections that occur in adolescence or early adulthood often result in infectious mononucleosis (IM), characterized by pharyngitis, cervical lymph node enlargement, fatigue and fever; complications can occur in around 1% of patients. Infectious mononucleosis is associated with an increased risk of Hodgkin lymphoma. EBV is also associated with a variety of malignancies, including gastric carcinoma, nasopharyngeal carcinoma, Hodgkin lymphoma and Burkitt lymphoma. EBV caused ~1% of all global cancers in 2002. EBV also causes Post transplant lymphoproliferative disorder (PTLD), a complication of solid organ transplants (SOT) and allogeneic hematologic stem cell transplants (HSCT).

This MarketVIEW This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Epstein-barr virus (EBV) vaccines across Western economies until 2035. The model contains value ($ m) and volume (mio doses) predictions per vaccine target segment along with timeframe, pricing and penetration estimates for three target product profiles (TPPs). The product also includes an in depth review of latest EBV epidemiological trends, treatments/guidelines and latest developments in R&D.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV056 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2015 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains